Online Presentation: Breakthrough Treatment Of Pain (OTC:NPHC)
StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and is informing potential investors in regards to the online webinar conference call with the Chairman and CEO, Rik J Deitsch, of which he is holding on his own terms. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).
Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when it announced the launch of Cobroxin, a safe and effective over-the-counter treatment for chronic pain. Unlike many popular pain medicines, Cobroxin does not rely on opiates or acetaminophen for its pain relieving effects. Instead, it uses small peptides from the venom of one of the deadliest animals on Earth – the cobra. Join Nutra Pharma’s Chairman and CEO, Rik J Deitsch, as he explores the science behind this revolutionary new pain killer and how Cobroxin will change the way chronic pain is treated in America and abroad.
The company also seems to have arrived on the scene for stage 2 pain relief at an ideal time, seeing as how the FDA has recently issued warnings on products that contain Ibuprophen. With the prescription pain relief market totaling nearly $14 billion and the over-the-counter (OTC) pain relief market totaling $8 billion, expected Nutra Pharma to enter FDA clinical trials in the near future with almost certain success, seeing as how it has proven to be more powerful than morphine with less side effects and no addictive properties.
Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. It is primarily intended to help with lower back pain, migraines, neck aches, shoulder pain, cramps, neuralgia, joint pain and pain associated with repetitive stress and arthritis.
Nutra Pharma plans to introduce Cobroxin through retailers across the country and are continuing to work diligently to place Cobroxin on retail shelves as quickly as possible. It is expected Cobroxin will be available at several leading retailers as early as October.
Cobroxin will have a suggested retail price of $18.99 for the oral spray and $19.95 for the topical gel, making it one of the most affordable analgesics for moderate to severe chronic pain.
To learn more about Cobroxin, be sure to visit the product website at www.Cobroxin.com
ONLINE WEBINAR DETAILS:
Date: Thursday, September 10, 2009
Time: 9:00 PM – 10:30 PM ET
To sign up and join the Webinar, visit www2.gotomeeting.com/register/136863971
About Nutra Pharma Corp.
Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
For more financial news visit www.StocksHaven.com
Disclosure: Position in NPHC
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- Founder and Lead Investment Analyst
- StocksHaven Investments
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.